Ísrael - hebreska - Ministry of Health

neopharm (israel) 1996 ltd - calcium chloride dihydrate; fish oil; glucose monohydrate; glycine; l- alanine; l- isoleucine; l- leucine; l- lysine acetate; l- methionine; l- phenylalanine; l- proline; l- serine; l- threonine; l- tryptophan; l- tyrosine; l- valine; l-arginine; l-histidine; magnesium sulfate heptahydrate; olive oil; potassium chloride; sodium acetate trihydrate; sodium glycerophosphate hydrated; soya bean oil, refined; taurine; triglycerides, medium-chain; zinc sulfate heptahydrate - תחליב לאינפוזיה - soya bean oil, refined 60 g / 1000 ml; glucose monohydrate 462 g / 1000 ml; zinc sulfate heptahydrate 0.0178 g / 1000 ml; sodium acetate trihydrate 4.1 g / 1000 ml; potassium chloride 3.48 g / 1000 ml; magnesium sulfate heptahydrate 1.92 g / 1000 ml; sodium glycerophosphate hydrated 3.48 g / 1000 ml; calcium chloride dihydrate 0.574 g / 1000 ml; l- tyrosine 0.4 g / 1000 ml; l- tryptophan 2 g / 1000 ml; taurine 1 g / 1000 ml; l- threonine 4.4 g / 1000 ml; l- serine 6.5 g / 1000 ml; l- proline 11.2 g / 1000 ml; l- phenylalanine 5.1 g / 1000 ml; l- methionine 4.3 g / 1000 ml; l- valine 6.2 g / 1000 ml; l- lysine acetate 9.3 g / 1000 ml; l- leucine 7.4 g / 1000 ml; l- isoleucine 5.0 g / 1000 ml; l-histidine 3.0 g / 1000 ml; glycine 11.0 g / 1000 ml; l-arginine 12.0 g / 1000 ml; l- alanine 14.0 g / 1000 ml; fish oil 30 g / 1000 ml; olive oil 50 g / 1000 ml; triglycerides, medium-chain 60 g / 1000 ml

Ísrael - hebreska - Ministry of Health

neopharm (israel) 1996 ltd - fish oil; glucose monohydrate; glycine; l- alanine; l- isoleucine; l- lysine acetate; l- methionine; l- phenylalanine; l- proline; l- serine; l- threonine; l- tryptophan; l- tyrosine; l- valine; l-arginine; l-histidine; l-leucine; olive oil; soya bean oil, refined; taurine; triglycerides, medium-chain - תחליב לאינפוזיה - fish oil 30 g / 1000 ml; olive oil 50 g / 1000 ml; triglycerides, medium-chain 60 g / 1000 ml; soya bean oil, refined 60 g / 1000 ml; glucose monohydrate 462 g / 1000 ml; l- valine 6.2 g / 1000 ml; l- tyrosine 0.40 g / 1000 ml; l- tryptophan 2 g / 1000 ml; l- threonine 4.4 g / 1000 ml; taurine 1 g / 1000 ml; l- serine 6.5 g / 1000 ml; l- proline 11.2 g / 1000 ml; l- phenylalanine 5.1 g / 1000 ml; l- methionine 4.3 g / 1000 ml; l- lysine acetate 9.3 g / 1000 ml; l-leucine 7.4 g / 1000 ml; l- isoleucine 5 g / 1000 ml; l-histidine 3 g / 1000 ml; glycine 11 g / 1000 ml; l-arginine 12 g / 1000 ml; l- alanine 14 g / 1000 ml

Ísrael - hebreska - Ministry of Health

lapidot medical import and marketing ltd - acetyltyrosine 1.23 g/l; arginine 9.2 g/l - solution for infusion - solutions for parenteral nutrition - parenteral nutrition and fluid substitution prophylaxis and therapy of protein deficiency or increased protein needs.

Ísrael - hebreska - Ministry of Health

lapidot medical import and marketing ltd - acetylcysteine 0.68 g/l; acetyltyrosine 1.23 g/l - solution for infusion - solutions for parenteral nutrition - parenteral nutrition and fluid substitution prophylaxis and therapy of protein deficiency or increased protein needs.

Ísrael - hebreska - Ministry of Health

megapharm ltd - nitisinone - קפסולה קשיחה - nitisinone 2 mg - nitisinone - nitisinone - treatment of patients with confirmed diagnosis of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine

Ísrael - hebreska - Ministry of Health

megapharm ltd - nitisinone - קפסולה קשיחה - nitisinone 5 mg - nitisinone - nitisinone - treatment of patients with confirmed diagnosis of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine

Ísrael - hebreska - Ministry of Health

megapharm ltd - nitisinone - קפסולה קשיחה - nitisinone 10 mg - nitisinone - nitisinone - treatment of patients with confirmed diagnosis of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine

Ísrael - hebreska - Ministry of Health

medison pharma ltd - fostamatinib as disodium hexahydrate - טבליות מצופות פילם - fostamatinib as disodium hexahydrate 100 mg - fostamatinib

Ísrael - hebreska - Ministry of Health

medison pharma ltd - fostamatinib as disodium hexahydrate - טבליות מצופות פילם - fostamatinib as disodium hexahydrate 150 mg - fostamatinib

Ísrael - hebreska - Ministry of Health

novartis israel ltd - lapatinib as ditosylate monohydrate - טבליות מצופות פילם - lapatinib as ditosylate monohydrate 250 mg - protein kinase inhibitors - tykerb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress her2 (erbb2);• in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting (see section 5.1).• tykerb is indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the her2 receptor for whom hormonal therapy is indicated. tykerb in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.